abstract |
In one aspect, the present invention relates to the discovery that β-Klotho is the primary cell surface receptor for FGF21, with FGFR1c functioning as a catalytic subunit that ultimately induces intracellular signaling. In one aspect, the invention provides compositions and methods useful in the treatment or prevention of endocrine FGF related diseases or disorders. |